HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research[1][2].
Molecular Weight:
153714 (average)
Purity:
97.76
Target:
Antibody-Drug Conjugates (ADCs),PD-1/PD-L1
Application Notes:
MCE Product type: ADC Related
* VAT and and shipping costs not included. Errors and price changes excepted
